Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
5.68
+0.14 (2.53%)
At close: Mar 28, 2024, 4:00 PM
5.62
-0.06 (-1.06%)
After-hours: Mar 28, 2024, 6:09 PM EDT
2.53%
Market Cap 640.62M
Revenue (ttm) 5.72M
Net Income (ttm) -110.57M
Shares Out 112.79M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,207,791
Open 5.54
Previous Close 5.54
Day's Range 5.51 - 5.76
52-Week Range 1.11 - 6.40
Beta 2.36
Analysts Strong Buy
Price Target 10.20 (+79.58%)
Earnings Date Nov 8, 2022

About ABSI

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 22, 2021
Employees 155
Stock Exchange NASDAQ
Ticker Symbol ABSI
Full Company Profile

Financial Performance

In 2023, Absci's revenue was $5.72 million, a decrease of -0.50% compared to the previous year's $5.75 million. Losses were -$110.57 million, 5.40% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $10.2, which is an increase of 79.58% from the latest price.

Price Target
$10.2
(79.58% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance ...

8 days ago - GlobeNewsWire

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten publi...

27 days ago - GlobeNewsWire

Absci Announces Pricing of Public Offering of Common Stock

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public ...

4 weeks ago - GlobeNewsWire

Absci Announces Proposed Public Offering of Common Stock

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten ...

4 weeks ago - GlobeNewsWire

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after

5 weeks ago - GlobeNewsWire

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” ...

2 months ago - GlobeNewsWire

Absci to Participate in the 26th Annual Needham Growth Conference

VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in...

3 months ago - GlobeNewsWire

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

3 months ago - GlobeNewsWire

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Act...

3 months ago - GlobeNewsWire

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform wi...

4 months ago - GlobeNewsWire

AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re...

Other symbols: AZN
4 months ago - Reuters

Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

4 months ago - GlobeNewsWire

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties

4 months ago - GlobeNewsWire

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

BARCELONA, Spain & VANCOUVER, Wash.--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI...

4 months ago - Business Wire

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo...

5 months ago - GlobeNewsWire

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day ...

6 months ago - GlobeNewsWire

Absci to Host R&D Day on October 4, 2023

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on We...

7 months ago - GlobeNewsWire

Biotech company Absci lays off 30 employees, about 15% of staff

Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.

7 months ago - GeekWire

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover afford...

8 months ago - GlobeNewsWire

Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer

Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth

8 months ago - GlobeNewsWire

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced that leading researchers at the California Institute of Te...

8 months ago - GlobeNewsWire

Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

8 months ago - GlobeNewsWire

Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit

VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

10 months ago - GlobeNewsWire

Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his...

10 months ago - GlobeNewsWire

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate

11 months ago - GlobeNewsWire